skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

52 Total results for product and free and sample content found

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

The evolving landscape of biosimilars

The evolving landscape of biosimilars

It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.

Topic Biosimilars

Generics Bulletin: ジェネリック&バイオシミラーニュース

Biosimilars Conference Coverage

Biosimilars Conference Coverage

Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

Topic biosimilars

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Scrip Preview Pharma Trends for 2020

Scrip Preview Pharma Trends for 2020

For Scrip’s annual preview, our journalists asked over 80 industry executives and experts for their predictions of the major trends for 2020. From AI to M&A, gene therapy to the upcoming US election, here’s what to watch for as we begin this  new decade.

Topic biosimilars biopharmaceutical

Generics Bulletin: ジェネリック&バイオシミラーニュース

Coherus Is Confident After US Ranibizumab Filing

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deal trends

Generics Bulletin: ジェネリック&バイオシミラーニュース

Alberta Is Second Canadian Province To Switch To Biosimilars

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Mylan/Biocon's Insulin Glargine Would Get A Respite Under US Budget Legislation

Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.

Generics Bulletin: ジェネリック&バイオシミラーニュース

Celltrion's Remsima SC Ready For Early 2020 Launch

Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

Generics Bulletin: ジェネリック&バイオシミラーニュース

Aurobindo Is Company Of The Year At GGB Awards

Article

Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.

Topic biosimilars

Generics Bulletin: ジェネリック&バイオシミラーニュース

Teva Debuts US Rituximab At A 10% Discount

Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

Topic biosimilars strategy

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。